1-14 of 14
David M. O'Malley
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Bridging the Gap from Bench to Bedside: A Call for In Vivo Preclinical Models to Advance Endometrial Cancer and Cervical Cancer Immuno-oncology Research

Laura Chambers, Paulina Haight, Julia Chalif, Yogita Mehra, Daniel Spakowicz, Floor J. Backes, Casey M. Cosgrove, David M. O’Malley, Roberto Vargas, Bradley R. Corr, Victoria L. Bae-Jump, Rebecca C. Arend
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (14): 2905–2909.
https://doi.org/10.1158/1078-0432.CCR-23-2570
Published: 15 July 2024
View article titled, Bridging the Gap from Bench to Bedside: A Call for <em>In Vivo</em> Preclinical Models to Advance Endometrial Cancer and Cervical Cancer Immuno-oncology Research
Open the PDF for Bridging the Gap from Bench to Bedside: A Call for <em>In Vivo</em> Preclinical Models to Advance Endometrial Cancer and Cervical Cancer Immuno-oncology Research in another window
Journal Articles

Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Yvette Drew, Jae-Weon Kim, Richard T. Penson, David M. O'Malley, Christine Parkinson, Patricia Roxburgh, Ruth Plummer, Seock-Ah Im, Martina Imbimbo, Michelle Ferguson, Ora Rosengarten, Neeltje Steeghs, Min Hwan Kim, Einav Gal-Yam, Daliah Tsoref, Jae-Hoon Kim, Benoit You, Maja De Jonge, Roy Lalisang, Eelke Gort, Sara Bastian, Kassondra Meyer, Laura Feeney, Nigel Baker, Mei-Lin Ah-See, Susan M. Domchek, Susana Banerjee, for the MEDIOLA Investigators
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 50–62.
https://doi.org/10.1158/1078-0432.CCR-23-2249
Published: 05 January 2024
View article titled, Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
Open the PDF for Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study in another window
Includes: Supplementary data
Journal Articles

Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study

Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, Renaud Sabatier, Jubilee Brown, Sharad Ghamande, Cara Mathews, David M. O'Malley, Rebecca Kristeleit, Valentina Boni, Adriano Gravina, Susana Banerjee, Rowan Miller, Joanna Pikiel, Mansoor R. Mirza, Ninad Dewal, Grace Antony, Yuping Dong, Eleftherios Zografos, Jennifer Veneris, Anna V. Tinker
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (22): 4564–4574.
https://doi.org/10.1158/1078-0432.CCR-22-3915
Published: 14 November 2023
View article titled, Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
Open the PDF for Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study in another window
Includes: Supplementary data
Journal Articles

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Rachel N. Grisham, Ignace Vergote, Susana Banerjee, Esther Drill, Elsa Kalbacher, Mansoor Raza Mirza, Ignacio Romero, Peter Vuylsteke, Robert L. Coleman, Felix Hilpert, Amit M. Oza, Anneke Westermann, Martin K. Oehler, Sandro Pignata, Carol Aghajanian, Nicoletta Colombo, David Cibula, Kathleen N. Moore, Josep M. del Campo, Regina Berger, Christian Marth, Jalid Sehouli, David M. O'Malley, Cristina Churruca, Gunnar Kristensen, Andrew Clamp, John Farley, Gopa Iyer, Isabelle Ray-Coquard, Bradley J. Monk
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (20): 4068–4075.
https://doi.org/10.1158/1078-0432.CCR-23-0621
Published: 13 October 2023
View article titled, Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
Open the PDF for Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract PO036: Patients with recurrent epithelial endometrial cancers (EEC) and Wnt signaling alterations demonstrated greater clinical benefit when treated with DKN-01 monotherapy

Rebecca Arend, Cesar Castro, Erica Hamilton, Kristopher LyBarger, Linda Duska, Michael Kagey, William Bradley, Jasgit Sachdev, Cynthia A. Sirard, David M. O'Malley
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (3_Supplement): PO036.
https://doi.org/10.1158/1557-3265.ENDOMET20-PO036
Published: 01 February 2021
View article titled, Abstract PO036: Patients with recurrent epithelial endometrial cancers (EEC) and <em>Wnt</em> signaling alterations demonstrated greater clinical benefit when treated with DKN-01 monotherapy
Journal Articles

Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis

Amanda N. Fader, Dana M. Roque, Eric Siegel, Natalia Buza, Pei Hui, Osama Abdelghany, Setsuko Chambers, Angeles Alvarez Secord, Laura Havrilesky, David M. O'Malley, Floor J. Backes, Nicole Nevadunsky, Babak Edraki, Dirk Pikaart, William Lowery, Karim ElSahwi, Paul Celano, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, Alessandro D. Santin
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (15): 3928–3935.
https://doi.org/10.1158/1078-0432.CCR-20-0953
Published: 03 August 2020
View article titled, Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis
Open the PDF for Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis in another window
Includes: Supplementary data
Journal Articles

Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218

Angeles Alvarez Secord, Kirsten Bell Burdett, Kouros Owzar, David Tritchler, Alexander B. Sibley, Yingmiao Liu, Mark D. Starr, J. Chris Brady, Heather A. Lankes, Herbert I. Hurwitz, Robert S. Mannel, Krishnansu S. Tewari, David M. O'Malley, Heidi Gray, Jamie N. Bakkum-Gamez, Keiichi Fujiwara, Matthew Boente, Wei Deng, Robert A. Burger, Michael J. Birrer, Andrew B. Nixon
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (6): 1288–1296.
https://doi.org/10.1158/1078-0432.CCR-19-0226
Published: 13 March 2020
View article titled, Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218
Open the PDF for Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218 in another window
Includes: Supplementary data
Journal Articles

Abstract GMM-048: CTDNA RESPONSE TO THE PARP INHIBITOR RUCAPARIB PREDICTS PROGRESSION-FREE SURVIVAL AND BEST OVERALL RESPONSE ON THE ARIEL2 TRIAL

Anna Piskorz, David Robertson, Kevin K. Lin, James Morris, Elaina Mann, Amit Oza, Robert L. Coleman, David M. O'Malley, Michael Friedlander, Janiel M. Cragun, Ling Ma, Heidi Giordano, Iain A. McNeish, Elizabeth Swisher, James Wason, James D. Brenton
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22_Supplement): GMM-048.
https://doi.org/10.1158/1557-3265.OVCASYMP18-GMM-048
Published: 15 November 2019
View article titled, Abstract GMM-048: CTDNA RESPONSE TO THE PARP INHIBITOR RUCAPARIB PREDICTS PROGRESSION-FREE SURVIVAL AND BEST OVERALL RESPONSE ON THE ARIEL2 TRIAL
Journal Articles

Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody–Drug Conjugate Mirvetuximab Soravtansine

Ursula A. Matulonis, Michael J. Birrer, David M. O'Malley, Kathleen N. Moore, Jason Konner, Lucy Gilbert, Lainie P. Martin, Todd M. Bauer, Amit M. Oza, Karim Malek, Jan Pinkas, Stella K. Kim
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (6): 1727–1736.
https://doi.org/10.1158/1078-0432.CCR-18-2474
Published: 15 March 2019
View article titled, Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody–Drug Conjugate Mirvetuximab Soravtansine
Open the PDF for Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody–Drug Conjugate Mirvetuximab Soravtansine in another window
Journal Articles

Abstract PR06: ARIEL3: A phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC)

Robert L. Coleman, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I. Weberpals, Andrew Clamp, Giovanni Scambia, Alexandra Leary, Robert W. Holloway, David M. O’Malley, Terri Cameron, Lara Maloney, Sandra Goble, Kevin Lin, James Sun, Heidi Giordano, Jonathan A. Ledermann
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (15_Supplement): PR06.
https://doi.org/10.1158/1557-3265.OVCA17-PR06
Published: 01 August 2018
View article titled, Abstract PR06: ARIEL3: A phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC)
Journal Articles

Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials

Steven J. Skates, Mark H. Greene, Saundra S. Buys, Phuong L. Mai, Powel Brown, Marion Piedmonte, Gustavo Rodriguez, John O. Schorge, Mark Sherman, Mary B. Daly, Thomas Rutherford, Wendy R. Brewster, David M. O'Malley, Edward Partridge, John Boggess, Charles W. Drescher, Claudine Isaacs, Andrew Berchuck, Susan Domchek, Susan A. Davidson, Robert Edwards, Steven A. Elg, Katie Wakeley, Kelly-Anne Phillips, Deborah Armstrong, Ira Horowitz, Carol J. Fabian, Joan Walker, Patrick M. Sluss, William Welch, Lori Minasian, Nora K. Horick, Carol H. Kasten, Susan Nayfield, David Alberts, Dianne M. Finkelstein, Karen H. Lu
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (14): 3628–3637.
https://doi.org/10.1158/1078-0432.CCR-15-2750
Published: 13 July 2017
View article titled, Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials
Open the PDF for Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials in another window
Includes: Supplementary data
Journal Articles

Abstract AP27: FEASIBILITY OF MONITORING RESPONSE TO THE PARP INHIBITOR RUCAPARIB WITH TARGETED DEEP SEQUENCING OF CIRCULATING TUMOR DNA (CTDNA) IN WOMEN WITH HIGH GRADE OVARIAN CARCINOMA ON THE ARIEL2 TRIAL

Anna Piskorz, Kevin K. Lin, James Morris, Elaina Mann, Amit Oza, Robert L. Coleman, David M. O'Malley, Michael Friedlander, Janiel M. Cragun, Ling Ma, Heidi Giordano, Nitzan Rosenfeld, Mitch Raponi, Iain A. McNeish, Elizabeth Swisher, James D. Brenton
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (11_Supplement): AP27.
https://doi.org/10.1158/1557-3265.OVCASYMP16-AP27
Published: 31 May 2017
View article titled, Abstract AP27: FEASIBILITY OF MONITORING RESPONSE TO THE PARP INHIBITOR RUCAPARIB WITH TARGETED DEEP SEQUENCING OF CIRCULATING TUMOR DNA (CTDNA) IN WOMEN WITH HIGH GRADE OVARIAN CARCINOMA ON THE ARIEL2 TRIAL
Journal Articles

Abstract AP28: BRCA1 and RAD51C Promoter Hypermethylation Confer Sensitivity to PARP Inhibitors in Patients with Platinum Sensitive Ovarian Carcinoma

Elizabeth Swisher, Maria Harrell, Kevin K. Lin, Clare Scott, Sandra Goble, Amit Oza, Robert L. Coleman, Gottfried Konecny, Anna V. Tinker, David M. O'Malley, Rebecca Kristeleit, Ling Ma, James Brenton, Katherine Bell-McGuinn, Ana Oaknin, Alexandra Leary, Elaina Mann, Heidi Giordano, Mitch Rapon, Iain McNeish, Scott H. Kaufmann
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (11_Supplement): AP28.
https://doi.org/10.1158/1557-3265.OVCASYMP16-AP28
Published: 31 May 2017
View article titled, Abstract AP28: <em>BRCA1</em> and <em>RAD51C</em> Promoter Hypermethylation Confer Sensitivity to PARP Inhibitors in Patients with Platinum Sensitive Ovarian Carcinoma
Journal Articles

Abstract A11: NGS-based tumor genomic profiling to identify ovarian cancer patients who benefit from the PARP inhibitor rucaparib.

Iain A. McNeish, Kevin K. Lin, James X. Sun, Sandra Goble, Amit Oza, Robert L. Coleman, Clare L. Scott, Gottfried Konecny, Anna V. Tinker, David M. O'Malley, Rebecca Kristeleit, Ling Ma, James D. Brenton, Katherine Bell-McGuinn, Ana Oaknin, Alexandra Leary, Elaina Mann, Heidi Giordano, Roman Yelensky, Mitch Raponi, Elizabeth Swisher
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (2_Supplement): A11.
https://doi.org/10.1158/1557-3265.OVCA15-A11
Published: 15 January 2016
View article titled, Abstract A11: NGS-based tumor genomic profiling to identify ovarian cancer patients who benefit from the PARP inhibitor rucaparib.